Does focal heterogeneity affect survival in postoperative ipsilateral multifocal and multicentric breast cancers?
Rev. Assoc. Med. Bras. (1992, Impr.)
;
68(3): 405-412, Mar. 2022. tab
Article
Dans Anglais
|
LILACS-Express
| LILACS
| ID: biblio-1376129
ABSTRACT
SUMMARY OBJECTIVE:
In multicentric/multifocal breast tumors, there may be immunological and histological differences between foci that may affect survival and treatment choice. We aimed to evaluate the effect of focal heterogeneity seen in multicentric/multifocal breast tumors on survival.METHODS:
We retrospectively collected and analyzed the clinicopathological data of 89 female patients with multifocal/multicentric breast cancer, whose surgical and medical treatment was completed and who were followed up for 5 years.RESULTS:
Of all patients, 29.2% (26/89) were heterogeneous. Heterogeneity of these foci was as follows histologic heterogeneity of index foci (mix type) 15.7% (14/89), histologic heterogeneity of inter-foci 7.9% (7/89), and immunohistochemical heterogeneity of inter-foci 10.1% (9/89). When additional foci were evaluated, oncological therapy was changed for 3 (3.3%) of 89 patients. Heterogeneity does not have a significant (p>0.05) effect on recurrence and survival in multicentric/multifocal breast cancers. Pathological N stage is an independent risk factor for disease-free survival (hazard ratio=2.29, 95% confidence interval=1.39-3.76, p=0.001).CONCLUSIONS:
In multifocal/multicentric breast cancers, less than 4% of patients may experience heterogeneity requiring change in the therapeutic decision. However, heterogeneity does not have a significant effect on recurrence and survival in multifocal/multicentric breast cancers. The pathological N stage is an independent risk factor for disease-free survival.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Type d'étude:
Étude pronostique
/
Facteurs de risque
langue:
Anglais
Texte intégral:
Rev. Assoc. Med. Bras. (1992, Impr.)
Thème du journal:
EducaÆo em Sa£de
/
GestÆo do Conhecimento para a Pesquisa em Sa£de
/
Médicament
Année:
2022
Type:
Article
Pays d'affiliation:
Turquie
Institution/Pays d'affiliation:
Health Sciences University Turkish Ministry of Health İstanbul Research and Training Hospital/TR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS